A phase 1/2 trial of ORIN1001, a first-in-class IRE1 inhibitor, in patients with advanced solid tumors.Nashat Gabrail, Ai‐Min Hui, Anthony Elias et al.|Journal of Clinical Oncology|2021Cited by 25